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Abstract
Background: Aptamers are oligonucleotides displaying specific binding properties for a predetermined target.
They are selected from libraries of randomly synthesized candidates through an in vitro selection process termed
SELEX (Systematic Evolution of Ligands by EXponential enrichment) alternating selection and amplification steps.
SELEX is followed by cloning and sequencing of the enriched pool of oligonucleotides to enable comparison of
the selected sequences. The most represented candidates are then synthesized and their binding properties are
individually evaluated thus leading to the identification of aptamers. These post-selection steps are time
consuming and introduce a bias to the expense of poorly amplified binders that might be of high affinity and are
consequently underrepresented. A method that would circumvent these limitations would be highly valuable.
Results: We describe a novel homogeneous solution-based method for screening large populations of
oligonucleotide candidates generated from SELEX. This approach, based on the AlphaScreen
® technology, is
carried out on the exclusive basis of the binding properties of the selected candidates without the needs of
performing a priori sequencing. It therefore enables the functional identification of high affinity aptamers. We
validated the HAPIscreen (High throughput APtamer Identification screen) methodology using aptamers targeted
to RNA hairpins, previously identified in our laboratory. We then screened pools of candidates issued from SELEX
rounds in a 384 well microplate format and identify new RNA aptamers to pre-microRNAs.
Conclusions: HAPIscreen, an Alphascreen
®-based methodology for the identification of aptamers is faster and less
biased than current procedures based on sequence comparison of selected oligonucleotides and sampling binding
properties of few individuals. Moreover this methodology allows for screening larger number of candidates. Used
here for selecting anti-premiR aptamers, HAPIscreen can be adapted to any type of tagged target and is fully
amenable to automation.
Background
Aptamers are DNA, RNA or chemically-modified oligo-
nucleotides selected from random pools of candidates
containing up to 10
15 different sequences on the basis of
their ability to bind to other molecules [1-3] or to cata-
lyze predetermined reactions [4,5]. Within these mole-
cules, intra-molecular folding generates up to 10
15
different structures that can be screened against a prede-
termined target for a chosen function, most often specific
binding. Alternative steps of selection and amplification
of selected candidates progressively enrich the pool in
sequences that are exquisitely adapted to the recognition
of the molecule of interest. To date aptamers have been
selected against many different types of targets: small
organic compounds, proteins, nucleic acids and complex
scaffolds such as intact viruses or live cells [6,7]. Aptamer
molecules share essential properties with antibodies such
as high affinity and specificity. In addition, aptamers offer
an alternative for the recognition of molecules such as
toxins against which no antibody can be easily raised or
for use under conditions that lead to protein denatura-
tion [8,9]. At last, aptamers that are chemically synthe-
sized on solid supports can readily be conjugated to
different pending groups making them versatile tools for
the labelling or the detection of their cognate target.
They are of high interest for analytical technology
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probes have already been designed. These molecules are
also of high potential value in medicine [13] as for
instance an anti-VEGF aptamer has been recently
approved by the Food and Drug Administration for the
treatment of age-related macular degeneracy [14]. Several
other molecules are currently being evaluated in clinical
trials [15].
Aptamers are generally obtained by systematic evolu-
tion of ligands by exponential enrichment (SELEX)
[16,17] even though a selection process without any
amplification step (non-SELEX) has been previously
described [18,19]. The current approaches require
sequencing of the selected clones at the end of the in
vitro selection. This is followed by a limiting step relying
on sequence comparison and individual evaluation of few
candidates for the identification of aptamers (Figure 1).
This methodology is slow, incompatible with automation
and is strongly biased since efficiently amplified poor affi-
nity binders may mask low copy/high affinity aptamer
candidates.
Given the increasing demand for aptamers [13] it
would therefore be more efficient to screen directly for
the desired property i.e. affinity of the target for a candi-
date (Figure 1). To this end we developed a functional
screen downstream of the SELEX pipeline that relies on
the AlphaScreen
® technology [20,21]. AlphaScreen
® is
based on the use of both Donor (D, photosensitizer) and
Acceptor (A, chemiluminescer) microbeads. Each bead
is conjugated to one of the two potential interacting
partners. A fluorescent signal is produced when both A
and D beads are brought into proximity, thus reporting
for the interaction between the biomolecular partners
captured on the two beads [20]. This technology has
been used for monitoring the interaction between var-
ious classes of molecules such as for instance protein/
protein [22-24] or protein/RNA interactions [25]. In the
present report, we demonstrate the interest of HAPIsc-
reen (High throughput APtamer Identification screen),
an AlphaScreen
®-based method for the detection of
aptamers targeted to different RNA hairpins of eukaryo-
tic or viral origin.
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Figure 1 Hapiscreen flowchart. The different steps of the HAPIscreen methodology are indicated (right) in comparison to that of the standard
SELEX method (left).
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In the AlphaScreen
® technology, Donor (D) and Accep-
tor (A) microbeads bear photosensitizing (phtalocyanin)
and chemoluminescent molecules (rubrene), respec-
tively. Laser excitation of the D beads at 680 nm causes
ambient oxygen to be converted to the singlet state by
phtalocyanin. Singlet oxygen species activate in turn a
cascade of chemiluminescent reactions within the A
beads leading to rubrene fluorescence detected between
520-620 nm using a photomultiplier tube-based micro-
plate reader. A signal is produced when the A and D
beads are brought into proximity (< 200 nm) through the
interaction between two molecules of interest respec-
tively immobilized on the two beads [20] (Figure 2A).
Therefore monitoring the emission signal allows for the
detection of complex formation. We used this technology
for monitoring the interactions between a candidate apta-
mer (RNA oligomer) and its target (RNA hairpin). In the
assay described here, D beads are conjugated to the target
and A beads to the candidate to be tested. This is
repeated for a number of candidates issued from a given
SELEX round and the emission specific to each pair is
measured. Candidates generating a signal are picked and
those corresponding to the strongest signal subsequently
sequenced for further characterization (Figure 1).
To demonstrate the interest of HAPIscreen for the
detection of aptamers targeted to different eukaryotic
RNA hairpins, we undertook a proof of concept phase
showing its applicability to monitor a previously charac-
terized HIV-1 RNA-aptamer association and to evaluate
pools of HCV RNA-aptamer complexes. This was fol-
lowed by the integration of a selection/evaluation pro-
cess into an automated-SELEX/AlphaScreen
® pipeline
allowing for identification of a large number of high affi-
nity candidate aptamers to pre-microRNAs (premiRs).
Monitoring RNA-RNA complexes with AlphaScreen
®
In the proof of concept phase, we focused on a RNA-
RNA complex that we previously characterized in great
detail [26-28]. AlphaScreen
® was used to quantify the
interaction between the trans-activating responsive
(TAR) RNA element of HIV-1 [29] and a RNA aptamer,
R06 identified from a random library of oligonucleotides
(Figure 2). These two oligoribonucleotides adopt a stem-
loop structure, display complementary sequences in the
apical loop (Figure 2C) and were demonstrated to give
rise to loop-loop (also called kissing) interactions.
Increasing concentrations (0-40 nM) of digoxigenin-
coupled R06 (dig-R06) were incubated in the presence
of increasing concentrations of biotin-coupled TAR
(biot-TAR), and constant amounts of streptavidin-D and
anti-Dig-A beads. Such titration experiments were car-
ried out at various biot-TAR concentrations ranging
from 0 to 40 nM (Figure 2B). This revealed typical bell-
shaped AlphaScreen
® signals showing a maximum for
40 nM biot-TAR and 10 nM dig-R06. Indeed as the
anti-Dig-A-bead amount remains constant, addition of
dig-R06 reaches a point at which it is no longer cap-
tured; consequently the excess of free dig-R06 competes
with immobilized R06 for interacting with TAR cap-
tured on D-beads. This results in a decrease in fluores-
cence signal.
To demonstrate the specificity of the interaction, a
competition assay was carried out in which increasing
concentrations of unconjugated (free) R06 (fR06) were
incubated in the presence of 10 nM dig-R06 and 40 nM
biot-TAR (Figure 3A). As expected AlphaScreen
® signal
decrease correlated with increasing concentrations of
fR06 added to the reaction, leading to an apparent IC50
of 16.7 nM ± 1.7 (Figure 3B), a value reflecting an affi-
nity in the same order of magnitude as that calculated
using surface plasmon resonance (SPR) [26,28].
Using thermal denaturation which was monitored by
UV absorption spectroscopy, SPR and gel-shift assays,
we previously showed that magnesium ions stabilized
the TAR-R06 complex [26]. In addition, we also used
the E. coli protein ROP, which is involved in the control
of the ColE1 plasmid copy number and specifically
recognizes loop-loop complexes. We previously demon-
strated that ROP was able to bind to the TAR-R06 com-
plex [30,31]. In the AlphaScreen
® assay described above,
increasing concentrations of ROP were added to biot-
TAR-dig-R06 complexes in the absence or in the pre-
sence of 3 mM MgCl2. The addition of 1 mM ROP
resulted in increased Alphascreen
® signal indicating the
formation of a highly stable ROP-R06-TAR kissing com-
plex (Figure 3C). A ~10 fold higher AlphaScreen
® signal
was observed for this ternary complex in the presence
o f3m MM g C l 2 compared to no magnesium (not
shown). These experiments demonstrate that this meth-
odology provides signals correlated to the affinity of the
complex. Indeed, no signal was detected for R06 variants
that do not complex with TAR, whereas conditions
known to increase the interaction (addition of magne-
sium or ROP protein) resulted in increased fluorescence
signals. Collectively these results demonstrate that
AlphaScreen
® is suitable for monitoring the interaction
between an aptamer and its target.
Monitoring the evolution of SELEX RNA pools with
HAPIscreen
Our objective was then to adapt this approach to the
screening of large pools of SELEX-derived sequences.
To this end, it was necessary to capture every selected
candidate on the A beads. The above methodology in
which biotinylated candidates are used would no longer
be easily adapted to such a goal. We rather considered
the use of a biotinylated anchor complementary to a
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Figure 2 HAPIscreen - proof of concept.( A) Scheme of the assay setup using a digoxigenin-tagged aptamer (R06) and a biotinylated target
RNA hairpin (TAR). The association of the two components is detected by using both Donor streptavidin (D) and Acceptor anti-digoxigenin (A)
coated AlphaScreen
® beads. The production of singlet oxygen upon laser excitation by D-phtalocyanin is monitored by the fluorescence
emission of A-rubrene beads. (B) Results obtained when increasing concentrations of dig-R06 were added to A and D beads for different biot-
TAR concentrations (from 0 to 40 nM as indicated on the right). (C) Secondary structures and/or sequences of the top part of the trans-
activating responsive (TAR) RNA element of HIV-1 (biot-TAR), 5’ end-extended TAR (rA-TAR), RNA aptamer R06 (dig-R06), domain II of the HCV
Internal Ribosome Entry Site (biot-DII), primer anchor (dig-primer). The latter was synthesized with 2’-O-methyl residues except at two positions
(underlined) where Locked Nucleic Acid residues were introduced in order to promote hybridization and to increase complex stability. Oligod
(T3CT21) anchor was used for capturing rA-TAR or the candidates from the M1 or M2 SELEX. The former were captured with biot-dT and the
latter with dig-dT oligonucleotides, respectively.
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Page 4 of 10pre-determined sequence on the candidates. Indeed
every candidate contains fixed sequences flanking the
random region, used in the SELEX process for the
amplification of the selected candidates. An oligomer com-
plementary to one of the flank efficiently allows for the
capture of every candidate, at least those for which this
region is not involved in a strong intra-molecular interac-
tion. In order to validate this anchor-based approach a
biotinylated oligod(T3CT21) (biot-dT) (Figure 2C) was
assayed in the presence of 10 nM dig-R06 and 40 nM
TAR bearing an oligor(A21GA3) tail (rA-TAR) (Figure 2C).
Increasing concentrations of biot-dT (Figure 4A) led to a
maximal AlphaScreen
® signal for rA-TAR concentrations
ranging from 40 to 80 nM, in accordance with a stoichio-
metric association between TAR and the biot-dT anchor
and the respective Donor and Acceptor bead capture
capacities under the current assay conditions. Therefore
the anchor-based methodology allows for monitoring
aptamer-target interactions.
We then used such a strategy for evaluating the evolu-
tion of populations derived from 7 rounds of RNA SELEX
previously carried out in our laboratory against the
domain II (DII) of the Hepatitis C Virus mRNA internal
ribosome entry site. This domain that folds as a hairpin
with a 7 nt loop, was used as the target. In vitro selection
against DII was previously demonstrated to produce high
affinity aptamers [32]. To monitor the evolution of the
RNA pool binding properties, candidates from the library
(T0) and from rounds one to seven (T1-T7) were trapped
on the acceptor beads using a digoxygenin-conjugated oli-
gonucleotide, dig-primer (Figure 2C) complementary to
their common 5’ end. AlphaScreen
® signals obtained with
D-beads carrying a 19 nucleotide long hairpin correspond-
ing to the top part of DII were detected from round 4 and
further increased at subsequent rounds, thus indicating
the progressive enrichment of the population in strong
binders (Figure 4B) in agreement with band shift assays
[32] and SPR experiments carried out with bimolecular
complexes formed between the immobilized HCV
target and the SELEX pools (Figure 4C). These results
demonstrate that the AlphaScreen
®-based approach
(HAPIscreen) could be undertaken for screening large col-
lections of selected candidates using a unique anchor
oligonucleotide.
Identification of aptamers in RNA pools selected against
premicroRNAs with HAPIscreen
We then used HAPIscreen for evaluating the outcome
of a SELEX experiment carried out using a RNA library
against pre-microRNAs (premiRs). PremiRs display
more or less perfect hairpin structures that are matured
into functional miRs [33,34]. Aptamers raised against
premiRs might consequently modulate miR interaction
B
0
25
50
75
100
1 10 100 1000
[fR06] nM
N
o
r
m
a
l
i
z
e
d
 
A
l
p
h
a
S
c
r
e
e
n

 
s
i
g
n
a
l
 
(
%
)
A
B
Excitation
680 nm
Emission
570 nm
fR06
fR06
fR06
DA
0 0.12 0.25 0.5 1 2
0
0.5
1
1.5
2
Rop (mM)
A
l
p
h
a
S
c
r
e
e
n
®
 
s
i
g
n
a
l
 
(
c
p
 
x
1
0
-
4
) C
Figure 3 AlphaScreen
®-based characterization of TAR-R06
interaction.( A) Competition assay setup. The assay was carried out
as described in Figure 2A in the presence of untagged R06 (fR06).
(B) Competition assay performed as described in A. Increasing
concentrations of fR06 were added to the reaction containing 10
nM of dig-R06 and 40 nM of biot-TAR and the AlphaScreen
® signal
was measured. Data are presented as percent of maximal signal
(mean ± SD) and are representative of at least 3 independent
experiments carried out in triplicate. (C) Rop binding assay to the
TAR-R06 kissing complex. Alphascreen
® signal was obtained with a
constant amount of biotinylated TAR and digoxiginated R06 (40 nM
and 10 nM, respectively) as described in Materials and Methods, in
the presence of increasing concentrations of the E. coli Rop protein.
Data are representative of 3 independent experiments carried out in
triplicate.
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Page 5 of 10with proteins involved in the maturation process and
impact on their regulatory function. Indeed oligonucleo-
tides complementary to premiRs were shown to modulate
the activity of miRs maturing enzymes [35,36]. SELEX was
performed against two mixtures M1 and M2 of three
h u m a np r e m i R se a c h( a ,b ,ca n dx ,y ,z ,r e s p e c t i v e l y )a s
described in Materials and Methods. At the end of seven
SELEX rounds, the selected candidates were cloned and
produced. Using HAPIscreen, candidates were trapped on
the acceptor beads using digoxygenin-conjugated oligod
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Figure 4 Screening of oligonucleotide pools.( A) TAR-R06 aptamer complexes were monitored as in Figure 2 except that a 5’ extended TAR
(rA-TAR) was immobilized on the beads through a biotinylated anchor oligonucleotide (biot-dT) (Figure 2C). Increasing concentrations of biot-dT
are incubated in the presence of 40 nM rA-TAR and 10 nM dig-R06. The results are representative of three independent experiments carried out
in triplicate (mean ± SD). Maximal AlphaScreen
® signal is obtained for stoichiometric concentrations of biot-dT and rA-TAR. (B) Monitoring the
evolution of SELEX pools to the HCV IRES domain II (biot-DII) (Figure 2C). Aptamer populations from 7 SELEX rounds (T1 to T7) as well as the
starting oligonucleotide pool (T0) were processed for AlphaScreen
® analysis as described in the Methods section. AlphaScreen
® signals are
reported for each population as the mean of three independent experiments ± SD carried out in duplicate. (C) Monitoring the evolution of
SELEX pools to the HCV IRES domain II (biot-DII) (Figure 2C) by SPR. Biot-DII was immobilized on a streptavidin-coated sensor chip (SAD200 m,
XanTec Bioanalytics). The populations were prepared at 500 nM in the SELEX buffer and were injected over the surface at 20 μl/min.
Dausse et al. Journal of Nanobiotechnology 2011, 9:25
http://www.jnanobiotechnology.com/content/9/1/25
Page 6 of 10(T3CT21) (dig-dT) (Figure 2C) complementary to their
identical 3’ end and individually assayed against each indi-
vidual biotin-tagged target. One hundred ninety-two
clones derived from the 7th round-enriched populations
against either M1 or M2 were screened in duplicate
blindly against the mixture of the three baits a, b and c or
against the premiR × alone, respectively. It should be
pointed out that the second experiment aims at identifying
the partner actually targeted by a given aptamer selected
against the mixture; repeating this experiment with immo-
bilized y or z would allow the complete assignment of
aptamers and targets. These experiments were carried out
in 384-well plates and led to the identification of hits
within both RNA populations (Figures 5A, B). Candidates
from each selection were picked according to their high
AlphaScreen
® signal (Figures 5A, B, red and grey dots,
respectively) and tested individually by Surface Plasmon
Resonance (Figure 5C). In the latter experiments, biotiny-
lated pre-miRs a, b, c and x were individually immobilized
on their respective sensor chip flow cells on which candi-
dates were injected. Nine out of 12 (SELEX to × from M2)
and 7 out of 12 (SELEX to a, b or c from M1) displayed
evaluated KD values lower than or equal to 30 nM for
unique-based or mixture-based target assays, respectively.
There was a fair agreement between both SPR and the
Alphascreen
® analyses even though the order of the sig-
nals was not rigorously the same with the two techniques
(Figures 5A and 4C). We also tested the behaviour of 5
candidates that generated a low Alphascreen
® signal using
SPR. This revealed that 4 out of the 5 candidates gave a
weak or no resonance signal (not shown).
High affinity aptamers identified by Alphascreen
®
were cloned and sequenced. As usual for in vitro selec-
tion we picked sequences displaying a high degree of
similarity and identical motifs. Sequence differences
likely account for the slight variation observed in
Alphascreen
® or SPR signals. Finally, using MFold [37],
aptamers from SELEX against M2 were predicted to
adopt a consensus hairpin structure with a loop contain-
ing several nucleotides complementary to pre-miR loops.
This suggested the formation of loop-loop aptamer/pre-
miR complexes as previously described for TAR apta-
mers [26]. These aptamers and the aptamer-premiRs
complexes are presently being characterized and will be
described in a forthcoming manuscript. Using a similar
approach, aptamers derived from SELEX against M1
also showed sequences complementary to premiR target
loop, allowing for the formation of 8 potential adjacent
base pairs but were not predicted to fold as hairpins.
Conclusion
Herein, we have developed a method that overcomes the
bias traditionally encountered in SELEX experiments.
Usually candidates selected at the end of the process are
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Figure 5 Screening of oligonucleotide pools.( A, B)
AlphaScreen
®-based analysis of individual candidates issued from
SELEX M1 against a mixed target population a, b and c (A) or from
SELEX M2 against the single target × (B). Error bars (horizontal bars
in Figure 5 A, B) represent the mean ± SD values of three distinct
AlphaScreen
® signal measurement for each SELEX population. For
M2 the 75 percentile above and below the average is shown. (C)
SPR analysis of twelve RNA candidates (corresponding to the red
dots in Figure 5A) binding to a premiR target from SELEX M1. 400
RU of the biotinylated target were immobilised on a streptavidin-
coated sensor chip (see Methods). The experiments were performed
in the SELEX buffer at 23°C and the sensorgrams were collected at
a flow rate of 20 μl/min. Candidates were injected at a
concentration of 500 nM.
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Page 7 of 10cloned and sequenced. Sequences and/or predicted sec-
ondary structures are then compared in order to gener-
ate families and to choose few representatives that are
then individually produced and characterized to identify
aptamers (Figure 1). HAPIscreen bypasses the sequence
comparison steps and directly allows for blind screening
of aptamer candidates based on their exclusive binding
properties rather than on sequence homologies. We
demonstrate that HAPIscreen is a high throughput tech-
nology that can be used to analyze large collections of
candidates. We used a 384-well plate format but HAP-
Iscreen could as well be adapted to a 1536-well plate
format. In addition, as the SELEX can be run simulta-
neously against a mixture of targets and the AlphaSc-
reen
® analysis can be carried out against individual
targets this predicts an increased discovery rate of apta-
mers. Moreover HAPIscreen is fully amenable to auto-
mation (currently the SELEX and the AlphaScreen
®
steps are independently automated) and can be adapted
for a wide range of targets due to the availability of differ-
ent tags/beads. HAPIscreen also proved to be faster than
traditional SELEX approaches as the process time was
shortened by at least 50% from the isolated SELEX popu-
lation to the identification of high affinity binders. The
preparation of hundreds of candidates being achieved on
an automated platform, this step is not time consuming.
Finally, HAPIscreen potentially increases the chance of
selecting orphan candidates (i.e. poorly amplified) by
allowing the evaluation of larger aptamer collections.
HAPIscreen therefore represents a major step forward in
aptamer discovery and identification.
Methods
Oligonucleotide synthesis and purification
DNA primers and the biotinylated DNA anchor biot-dT,
purchased either from Sigma or MWG Biotech, were
purified by HPLC. All RNA targets and the digoxygenin
2’-O-methyl-LNA anchor (dig-primer) were chemically
synthesized on an Expedite 8908 synthesizer (Applied
Biosystems, USA) and purified by electrophoresis on
denaturing 20% polyacrylamide, 7M urea gels. RNA can-
didates were synthesized by in vitro transcription using
T7 RNA polymerase.
AlphaScreen
® assays
The AlphaScreen
® technology was used to assess the
interaction between candidate oligonucleotides derived
from SELEX experiments, and biotinylated target. Bind-
ing assays were performed using white 384-well Opti-
plates (Perkin Elmer) in a total volume of 25 μl. The
AlphaScreen
® reagents (anti-dig-coated Acceptor beads
and streptavidin-coated Donor beads) were obtained
from PerkinElmer. biot-TAR and dig-R06 (see figure 2C
for oligonucleotide sequences) were prepared in a 10
mM sodium phosphate buffer, pH 7.2 at 20°C, contain-
ing 140 mM potassium chloride, 20 mM sodium chlor-
ide and 3 mM magnesium chloride. Prior to the
experiments the RNA samples were heated in this buffer
at 95°C for 1 min and 30 s and cooled down on ice for
10 min. The protein ROP, purified as previously
described [30], was prepared in this buffer with or with-
out magnesium chloride. For the analysis of SELEX
populations, denaturation and refolding of the candidate
aptamers and targets prior to reaction with the anchor
(biot-dT) was performed in water at 65°C for 3 min or
80°C for 1 min, respectively. After denaturation, candi-
date aptamer and target were quickly cooled down to 4°
C for 3 min and then equilibrated at room temperature
(RT) for 5 min before adding the selection buffer (20
mM sodium acetate, 140 mM potassium acetate, 3 mM
magnesium acetate, 20 mM HEPES; pH 7.4). Equal
volumes (5 μl) of each partner, candidate and target,
were incubated for 45 min at room temperature (RT), at
final concentrations of 0.2 μM and 0.625 μM, respec-
tively. In parallel Acceptor beads (20 μg/ml) were incu-
bated with dig-primer (0.625 μM) for 1 h at room
temperature in the selection buffer. Then, 10 μlo fe a c h
of the interacting partners were added to the plate, after
4 5 - m i ni n c u b a t i o na tR T ,5μl of Donor beads at a 20
μg/ml concentration were added to the mixture. All
manipulations involving AlphaScreen
® beads were per-
formed under subdued lighting. The plates were allowed
to incubate either 1 h or overnight in the dark at room
temperature. Light signal was detected by using an
EnVision
® multilabel plate reader from PerkinElmer.
In vitro selection
The RNA library used for the selections was obtained by
transcription of the DNA library (5’-GTGTGACCG
ACCGTGGTGC-N30-GCAGTGAAGGCTGGTAACC-
3’) as previously described [38]. Two different primers
P20 5’-GTGTGACCGACCGTGGTGC-3’ and 3’SL con-
taining the T7 transcription promoter (underlined) 5’-
TAATACGACTCACTATAGGTTACCAGCCTTCA
CTGC-3’ were used for PCR amplification. Oligonucleo-
tide P20 was also used to prime reverse transcription.
Selection steps were performed in the SELEX buffer (20
mM HEPES, pH 7.4 at 23°C, 20 mM sodium acetate,
140 mM potassium acetate and 3 mM magnesium acet-
ate) at 23°C on an in-house assembled automated work-
station (Tecan Freedom EVO 150). All steps (magnetic
bead separation, vacuum purification, PCR amplification
and transcription) were carried out in microplates. Two
parallel SELEX, each against 3 target premiRs, constitut-
ing mixtures M1 and M2, were performed on the auto-
mated workstation. For each SELEX, 3 μMo ft h eR N A
library was heated at 80°C for 1 min, cooled at 4°C for
3 min, placed at room temperature for 5 min and mixed
Dausse et al. Journal of Nanobiotechnology 2011, 9:25
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(50 μg of Streptavidin MagneSphere
® Paramagnetic Par-
ticles from Promega or 500 μg of Dynabeads M-280).
RNA candidates not retained by the beads were then
mixed and incubated for 10 min with 10 pmol of 3 dif-
ferent 3’ end biotinylated premiRs that were previously
immobilized on streptavidin beads. Unbound RNA was
removed and the beads were washed twice with 100 μl
of the SELEX buffer. The bound RNA candidates were
eluted from the premiRs by heating for 1 min at 75°C in
50 μl of water. RNA candidates were reverse-transcribed
with 200 units of M-MLV reverse transcriptase RNase
H
- Point mutant (Promega) for 50 min at 50°C. The
cDNA was amplified by PCR at 63°C with 20 units of
the DNA polymerase AmpliTaq Gold™ (PerkinElmer)
and the two primers P20 and 3’SL at 2 μM, during 25
cycles. RNA candidates were obtained by in vitro tran-
scription of the PCR products with the Ampliscribe T7
transcription kit from Epicentre Biotechnologies. After 2
first manual and 5 automated rounds of selection
against pre-miRs, carried out on an EVO150 (Tecan) in
house-assembled robot, selected candidates were cloned
using the TOPO TA cloning kit (Invitrogen).
Synthesis, capture and sequencing of the candidates
In order to generate candidates for high throughput
screening, we set up a second automated workstation
(Tecan Freedom EVO 200) equipped with a thermal
cycler, an orbital shaker, a magnetic particle separation
module and a vacuum separation module. Three hun-
dred and eighty four clones (192 clones from either M1
or M2 populations) from round 7 were produced blindly
on this second workstation. Candidates were directly
amplified from colonies with a 5’ end oligod(T21CT3)
(underlined) lengthened P20 5’-TTTTTTTTTTTTTTT
TTTTTTCTTTGTGTGACCGACCGTGGTGC-3’ and
the 3’SL 5’-TAATACGACTCACTATAGGTTAC-
CAGCCTTCACTGC-3’ primers allowing the addition of
an oligodA/T extension to the PCR products. RNAs
produced by transcription of these PCR amplifications
contained a 3’ end oligorA tail that was used to capture
them for the AlphaScreen
® tests with a digoxygenin-
conjugated oligonucleotide (dig-dT) (Figure 2C). Candi-
dates were sequenced using the BigDye Terminator v1.1
cycle sequencing kit (Applied Biosystems) according to
the manufacturer’s instructions.
Surface Plasmon Resonance analyses
SPR experiments were performed at 23°C with a BIA-
core™ 3000 apparatus. The biotinylated premiRs were
immobilised at 50 nM (300 to 400 RU) on SA (BIAcore,
GE Heathcare Life Sciences; Sweden) or SAD200 m sen-
sor chips (XanTech Bioanalytics; Germany) coated with
streptavidin. Aptamers were injected at 500 nM in the
SELEX buffer at a 20 μl/min flow rate. After each injec-
tion of the candidates, the target-surface was regener-
ated with a 1 min pulse of a mixture containing 40%
formamide, 30 mM EDTA and 3.6 M urea prepared in
milli-Q water. The sensorgrams were analysed with the
BIAeval software 4.1 as previously described [30]. Sen-
sorgrams were double-referenced [39].
Acknowledgements
We are grateful to Ms E. Daguerre (Inserm U869) for skilled technical assistance
and N. Pierre (Inserm U869) for oligonucleotides synthesis. We are indebted to
Dr S. Da Rocha Gomes for RNA SELEX against the domain II of the HCV mRNA
internal ribosome entry site. We thank Drs J. Rosenbaum and F. Darfeuille
(Bordeaux), M. Gait and M. Fabani (Cambridge) for critically reading the
manuscript. This work was supported by the “Conseil Régional d’Aquitaine” to
JJT; and by Inserm (Avenir); Institut National du Cancer; “Conseil Régional
d’Aquitaine"; and Fondation pour la Recherche Médicale to EC.
Author details
1Inserm U869, Institut Européen de Chimie et Biologie, 2 rue Robert Escarpit,
33706 Pessac, France.
2Inserm U1053 Avenir, Bat 1A, 146 rue Léo Saignat,
33076 Bordeaux, France.
3Université de Bordeaux, 146 rue Léo Saignat, 33076
Bordeaux, France.
Authors’ contributions
ED carried out, designed and analyzed the SELEX experiments. ST designed
and performed the Alphascreen
®® experiments and analyzed the data. LE
performed the manual and automated selection. CDP designed the
interaction models and participated in the SPR measurements. EC supervised
the Alphascreen
®® measurements. JJT conceived the study and participated
in its coordination. EC and JJT drafted the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 January 2011 Accepted: 3 June 2011 Published: 3 June 2011
ReferencesIn vitro selection of RNA molecules that bind specific
ligandsEllington AD, Szostak JW: In vitro selection of RNA molecules
that bind specific ligands. Nature 1990, 346:818-822.
2. Robertson DL, Joyce GF: Selection in vitro of an RNA enzyme that
specifically cleaves single-stranded DNA. Nature 1990, 344:467-468.
3. Tuerk C, Gold L: Systematic evolution of ligands by exponential
enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science
1990, 249:505-510.
4. Bartel DP, Szostak JW: Isolation of new ribozymes from a large pool of
random sequences [see comment]. Science 1993, 261:1411-1418.
5. Lehman N, Joyce GF: Evolution in vitro of an RNA enzyme with altered
metal dependence. Nature 1993, 361:182-185.
6. Dausse E, Da Rocha Gomes S, Toulmé JJ: Aptamers: a new class of
oligonucleotides in the drug discovery pipeline? Curr Opin Pharmacol
2009, 9:602-607.
7. Hall B, Arshad S, Seo K, Bowman C, Corley M, Jhaveri SD, Ellington AD: In
vitro selection of RNA aptamers to a protein target by filter
immobilization. Curr Protoc Mol Biol 2009, 24:23, Unit 24.
8. Tok JB, Fischer NO: Single microbead SELEX for efficient ssDNA aptamer
generation against botulinum neurotoxin. Chem Commun (Camb) 2008,
1883-1885.
9. Cruz-Aguado JA, Penner G: Determination of ochratoxin a with a DNA
aptamer. J Agric Food Chem 2008, 56:10456-10461.
10. Yan AC, Levy M: Aptamers and aptamer targeted delivery. RNA Biol 2009,
6.
11. Tombelli S, Mascini M: Aptamers as molecular tools for bioanalytical
methods. Curr Opin Mol Ther 2009, 11:179-188.
12. Mairal T, Cengiz Ozalp V, Lozano Sanchez P, Mir M, Katakis I, O’Sullivan CK:
Aptamers: molecular tools for analytical applications. Anal Bioanal Chem
2007, 390:989-1007.
Dausse et al. Journal of Nanobiotechnology 2011, 9:25
http://www.jnanobiotechnology.com/content/9/1/25
Page 9 of 1013. Keefe AD, Pai S, Ellington A: Aptamers as therapeutics. Nat Rev Drug
Discov 2010, 9:537-550.
14. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP:
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
Nat Rev Drug Discov 2006, 5:123-132.
15. Bunka DH, Platonova O, Stockley PG: Development of aptamer
therapeutics. Curr Opin Pharmacol 2010, 10:557-562.
16. Gold L, Brown D, He Y, Shtatland T, Singer BS, Wu Y: From oligonucleotide
shapes to genomic SELEX: novel biological regulatory loops. Proc Natl
Acad Sci USA 1997, 94:59-64.
17. Gopinath SC: Methods developed for SELEX. Anal Bioanal Chem 2007,
387:171-182.
18. Berezovski MV, Musheev MU, Drabovich AP, Jitkova JV, Krylov SN: Non-
SELEX: selection of aptamers without intermediate amplification of
candidate oligonucleotides. Nat Protoc 2006, 1:1359-1369.
19. Javaherian S, Musheev MU, Kanoatov M, Berezovski MV, Krylov SN:
Selection of aptamers for a protein target in cell lysate and their
application to protein purification. Nucleic Acids Res 2009, 37:e62.
20. Taouji S, Dahan S, Bosse R, Chevet E: Current Screens Based on the
AlphaScreen Technology for Deciphering Cell Signalling Pathways. Curr
Genomics 2009, 10:93-101.
21. Eglen RM, Reisine T, Roby P, Rouleau N, Illy C, Bosse R, Bielefeld M: The use
of AlphaScreen technology in HTS: current status. Curr Chem Genomics
2008, 1:2-10.
22. Bouchecareilh M, Caruso ME, Roby P, Parent S, Rouleau N, Taouji S,
Pluquet O, Bosse R, Moenner M, Chevet E: AlphaScreen-based
characterization of the bifunctional kinase/RNase IRE1alpha: a novel and
atypical drug target. J Biomol Screen 2010, 15:406-417.
23. Arcand M, Roby P, Bosse R, Lipari F, Padros J, Beaudet L, Marcil A, Dahan S:
Single-well monitoring of protein-protein interaction and
phosphorylation-dephosphorylation events. Biochemistry 2010,
49:3213-3215.
24. Caruso ME, Jenna S, Beaulne S, Lee EH, Bergeron A, Chauve C, Roby P,
Rual JF, Hill DE, Vidal M, et al: Biochemical clustering of monomeric
GTPases of the Ras superfamily. Mol Cell Proteomics 2005, 4:936-944.
25. Mills NL, Shelat AA, Guy RK: Assay Optimization and Screening of RNA-
Protein Interactions by AlphaScreen. J Biomol Screen 2007, 12:946-955.
26. Ducongé F, Di Primo C, Toulmé JJ: Is a closing “GA pair” a rule for stable
loop-loop RNA complexes? J Biol Chem 2000, 275:21287-21294.
27. Van Melckebeke H, Devany M, Di Primo C, Beaurain F, Toulmé JJ, Bryce DL,
Boisbouvier J: Liquid-crystal NMR structure of HIV TAR RNA bound to its
SELEX RNA aptamer reveals the origins of the high stability of the
complex. Proc Natl Acad Sci USA 2008, 105:9210-9215.
28. Lebars I, Legrand P, Aimé A, Pinaud N, Fribourg S, Di Primo C: Exploring
TAR-RNA aptamer loop-loop interaction by X-ray crystallography, UV
spectroscopy and surface plasmon resonance. Nucleic Acids Res 2008,
36:7146-7156.
29. Bannwarth S, Gatignol A: HIV-1 TAR RNA: the target of molecular
interactions between the virus and its host. Curr HIV Res 2005, 3:61-71.
30. Di Primo C, Lebars I: Determination of refractive index increment ratios
for protein-nucleic acid complexes by surface plasmon resonance. Anal
Biochem 2007, 368:148-155.
31. Watrin M, Von Pelchrzim F, Dausse E, Schroeder R, Toulmé JJ: In vitro
selection of RNA aptamers derived from a genomic human library
against the TAR RNA element of HIV-1. Biochemistry 2009, 48:6278-6284.
32. Da Rocha Gomes S, Dausse E, Toulmé JJ: Determinants of apical loop-
internal loop RNA-RNA interactions involving the HCV IRES. Biochem
Biophys Res Commun 2004, 322:820-826.
33. Zeng Y: Principles of micro-RNA production and maturation. Oncogene
2006, 25:6156-6162.
34. Chekulaeva M, Filipowicz W: Mechanisms of miRNA-mediated post-
transcriptional regulation in animal cells. Curr Opin Cell Biol 2009,
21:452-460.
35. Michlewski G, Guil S, Semple CA, Caceres JF: Posttranscriptional regulation
of miRNAs harboring conserved terminal loops. Mol Cell 2008, 32:383-393.
36. Lunse CE, Michlewski G, Hopp CS, Rentmeister A, Caceres JF, Famulok M,
Mayer G: An aptamer targeting the apical-loop domain modulates pri-
miRNA processing. Angew Chem Int Ed Engl 2010, 49:4674-4677.
37. Zuker M: Mfold web server for nucleic acid folding and hybridization
prediction. Nucleic Acids Res 2003, 31:3406-3415.
38. Dausse E, Cazenave C, Rayner B, Toulmé JJ: In vitro selection procedures
for identifying DNA and RNA aptamers targeted to nucleic acids and
proteins. Methods Mol Biol 2005, 288:391-410.
39. Myszka DG: Improving biosensor analysis. J Mol Recognit 1999, 12:279-284.
doi:10.1186/1477-3155-9-25
Cite this article as: Dausse et al.: HAPIscreen, a method for high-
throughput aptamer identification. Journal of Nanobiotechnology 2011
9:25.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Dausse et al. Journal of Nanobiotechnology 2011, 9:25
http://www.jnanobiotechnology.com/content/9/1/25
Page 10 of 10